Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

Company Information

13.06.2008

» Further clinical trial for a seasonal flu vaccine containing 
Intercell´s   adjuvant IC31® being initiated

» Intercell will be entitled to receive EUR 2 m milestone payment 
upon   the vaccination of the first human subject in the  clinical 
trial

Vienna (Austria), June 13, 2008 - Intercell AG (VSE: ICLL) today 
announced progress in its collaboration with Novartis to develop an 
improved Influenza vaccine. Novartis now has initiated its in-house 
development program with clinical trials designed to demonstrate 
safety and immunogenicity of a seasonal Influenza vaccine adjuvanted 
with IC31®. This triggers a milestone payment of EUR 2 m to 
Intercell. As part of the agreement between Novartis and Intercell, 
signed in July 2007, Novartis has an exclusive license for 
development of Intercell's IC31® adjuvant in novel influenza 
vaccines. As announced in February 2008 Intercell completed an 
initial Phase I clinical trial of the company's adjuvant IC31® in 
combination with the seasonal, trivalent influenza vaccine Agrippal® 
from Novartis. The IC31® adjuvanted vaccine showed an excellent 
safety and tolerability profile, which was comparable to the 
non-adjuvanted standard vaccine. Furthermore in all study groups 
vaccination with the test vaccine led to the induction of virus 
specific T-cells and protective levels of antibody responses against 
the three included influenza strains.

Gerd Zettlmeissl, CEO of Intercell, commented: "Intercell's IC31® has
shown excellent preclinical data and an encouraging profile in first 
trials in humans and we are confident that an influenza vaccine 
formulated with IC31® now further developed by Novartis has potential
to become a next generation vaccine."

About IC31®

Vaccines, based on antigens alone, are not sufficient to provide full
protection. Adjuvants are needed to educate the immune system to 
recognize and eliminate the pathogens efficiently. IC31® is an 
adjuvant that induces T-cell and B-cell responses by using a unique 
synthetic formulation which combines the immunostimulating properties
of an anti-microbial peptide, KLK, and an immunostimulatory 
oligodeoxynucleotide, ODN1a. The two component solution can be simply
mixed with antigens; no conjugation is required. Intercell currently 
uses IC31® in collaborations with a number of global vaccine 
companies and biotech companies. These collaborations include amongst
others the development of a tuberculosis vaccine in Phase I clinical 
trials, which has been partnered with the Danish Statens Serum 
Institut and Sanofi Pasteur.

end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market